Collaboration to support advances in pediatric HIV treatment and care in low-resource settings
11 December 2014 (Geneva, Switzerland) - As part of its continued commitment to ending pediatric HIV globally, the International AIDS Society (IAS) today announced a new collaboration with Janssen, the pharmaceutical companies of Johnson & Johnson in the IAS Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) program. In support of CIPHER, Janssen is providing a grant to accelerate research and advocacy around good clinical practices for and delivery of services to vulnerable children, and adolescents living with HIV.
According to the latest data from UNAIDS, while an estimated 12.9 million people were on HIV treatment by the end of 2013, only one quarter of the 3.2 million children in need were able to access treatment. As a result of this imbalance, more than 500 children die of AIDS every day. This new grant from Janssen will help combat these trends and ensure that the needs of children living with HIV are brought to the forefront of international discussions.
“We are very excited about this new collaboration with Janssen,” said Marissa Vicari, CIPHER Project Manager. “The private sector is an integral player in the fight against pediatric HIV, and Johnson & Johnson has a long legacy in promoting the health of children. We know that our combined efforts will have a tremendous impact on children in need.”
The Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) is a flagship paediatric research initiative of the International AIDS Society (IAS), aimed at optimizing clinical management and delivery of services to infants, children and adolescents affected by HIV in resource-limited settings through advocacy and research promotion. Initiated in 2012, the founding sponsor of CIPHER is ViiV Healthcare.
To help tackle the specific challenge of HIV treatment failure in children and adolescents, IAS has further extended its partnership with Janssen by joining the New Horizons Advancing Pediatric HIV Treatment initiative. This collaborative program is focused on advancing knowledge and action around the unique needs of children who have grown resistant to first-line HIV medicines, in partnership with Janssen, the Elizabeth Glaser Pediatric AIDS Foundation, Supply Chain Management System, and MAP International.
“Working with CIPHER is an important step in our mission to ensure that all children and adolescents living with advanced HIV have access to the care they need to stay healthy,” said Perry Mohammed, M.D., Global Medical Affairs Lead at Janssen. “One of the founding principles of the New Horizons initiative is an emphasis on partnerships and cross-sector collaboration. Janssen and CIPHER’s common vision of a world where no child dies of HIV will only be realized when all stakeholders join together and commit to fighting this battle as one, unified front.”
While the international community has dramatically scaled-up access to HIV treatment around the world, advances in pediatric care lag behind. Additionally, the adolescent HIV mortality rate – which is declining amongst all other age groups – is growing. More now than ever, programs like CIPHER and New Horizons are needed to ensure that these trends are reversed and to safeguard the health of children all over the world.
The Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) is a flagship paediatric research initiative of the International AIDS Society (IAS), aimed at optimizing clinical management and delivery of services to infants, children and adolescents affected by HIV in resource-limited settings through advocacy and research promotion. Initiated in 2012, CIPHER is supported by an unrestricted grant from ViiV Healthcare’s Paediatric Innovation Seed Fund. The content and structure of the project is guided by paediatric experts convened by the IAS.
The main objectives of CIPHER are:
- Promoting and investing in targeted research to address knowledge gaps/priority questions to optimize service delivery and clinical management of infants and children in resource-limited settings.
- Convening stakeholders and establishing collaboration mechanisms to strengthen communication, knowledge transfer and exchange among paediatric HIV cohorts.
- Advocacy and outreach to support evidence-informed clinical, policy and programmatic decision making.
CIPHER is designed to complement existing global initiatives and create partnerships with other organizations to maximize investment in paediatric HIV research and improve paediatric health outcomes. The first phase of the project consisted of building a solid scientific and programmatic foundation. A comprehensive needs assessment was conducted, including a literature review and key informant interviews with experts, which outlined a set of research priorities that has been used to inform and guide CIPHER.
About the IAS
The International AIDS Society (IAS) is the world's leading independent association of HIV professionals, with over 13,000 members from more than 180 countries working at all levels of the global response to AIDS. The IAS members include researchers from all disciplines, clinicians, public health and community practitioners on the frontlines of the epidemic, as well as policy and programme planners. The IAS is custodian of the biennial International AIDS Conference, which will be held in Durban, South Africa, 17-22 July 2016 and lead organizer of the IAS Conference on HIV Pathogenesis, Treatment and Prevention, which will be held in Vancouver, British Columbia, Canada, 19-22 July 2015.
www.iasociety.org | www.ias2015.org | www.aids2016.org
About Johnson & Johnson
Caring for the world, one person at a time…inspires and unites the people of Johnson & Johnson. We embrace research and science ‒ bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 128,000 employees at more than 275 Johnson & Johnson operating companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.
About the Janssen Pharmaceutical Companies of Johnson & Johnson The Janssen Pharmaceutical Companies of Johnson & Johnson are dedicated to addressing and solving the most important unmet medical needs of our time, including oncology (e.g., multiple myeloma and prostate cancer), immunology (e.g., rheumatoid arthritis, inflammatory bowel disease and psoriasis), neuroscience (e.g., schizophrenia, dementia and pain), infectious disease (e.g., HIV/AIDS, Hepatitis C and tuberculosis), and cardiovascular and metabolic diseases (e.g., diabetes). Driven by our commitment to patients, we develop sustainable, integrated healthcare solutions by working side-by-side with healthcare stakeholders, based on partnerships of trust and transparency. To learn more, visit www.janssen.com.
For more information: